NCT04912921View on ClinicalTrials.gov

Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19

NACompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

May 15, 2022

Study Completion Date

May 15, 2022

Conditions
InflammationCOVID19
Interventions
DIETARY_SUPPLEMENT

palmitoylethanolamide

4 tablets taken daily (2 in the am and 2 in the pm)

DIETARY_SUPPLEMENT

Placebo

4 tablets taken daily (2 in am and 2 in pm)

DIETARY_SUPPLEMENT

Curcumin

500 mg HydroCurc® twice a day

DIETARY_SUPPLEMENT

Control (microcrystalline cellulose)

2 tablets taken daily

Trial Locations (1)

85004

Arizona Biomedical Collaborative, Phoenix

All Listed Sponsors
lead

Arizona State University

OTHER

NCT04912921 - Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19 | Biotech Hunter | Biotech Hunter